As of 2025-10-28, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (2.42) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.17 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -176.4%.
The range of the Relative Valuation is (2.38) - (2.77) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 20.2x | 15.2x |
| Forward P/E multiples | 17.3x - 24.7x | 20.0x |
| Fair Price | (2.38) - (2.77) | (2.42) |
| Upside | -175.0% - -187.5% | -176.4% |
| Date | P/E |
| 2025-10-28 | -22.57 |
| 2025-10-27 | -23.04 |
| 2025-10-24 | -22.02 |
| 2025-10-23 | -21.66 |
| 2025-10-22 | -21.73 |
| 2025-10-21 | -22.67 |
| 2025-10-20 | -22.97 |
| 2025-10-17 | -21.29 |
| 2025-10-16 | -21.22 |
| 2025-10-15 | -21.44 |
| 2025-10-14 | -20.28 |
| 2025-10-13 | -20.20 |
| 2025-10-10 | -19.99 |
| 2025-10-09 | -21.00 |
| 2025-10-08 | -20.71 |
| 2025-10-07 | -21.44 |
| 2025-10-06 | -21.58 |
| 2025-10-03 | -20.57 |
| 2025-10-02 | -19.70 |
| 2025-10-01 | -19.48 |
| 2025-09-30 | -19.84 |
| 2025-09-29 | -19.70 |
| 2025-09-26 | -19.91 |
| 2025-09-25 | -19.70 |
| 2025-09-24 | -20.13 |
| 2025-09-23 | -20.57 |
| 2025-09-22 | -20.28 |
| 2025-09-19 | -20.49 |
| 2025-09-18 | -21.51 |
| 2025-09-17 | -20.35 |
| 2025-09-16 | -20.57 |
| 2025-09-15 | -21.22 |
| 2025-09-12 | -21.44 |
| 2025-09-11 | -21.73 |
| 2025-09-10 | -21.29 |
| 2025-09-09 | -21.80 |
| 2025-09-08 | -22.75 |
| 2025-09-05 | -21.51 |
| 2025-09-04 | -21.95 |
| 2025-09-03 | -22.67 |
| 2025-09-02 | -22.60 |
| 2025-08-29 | -22.82 |
| 2025-08-28 | -22.75 |
| 2025-08-27 | -21.88 |
| 2025-08-26 | -22.46 |
| 2025-08-25 | -22.02 |
| 2025-08-22 | -23.18 |
| 2025-08-21 | -23.18 |
| 2025-08-20 | -22.67 |
| 2025-08-19 | -22.09 |